About Michael Seiden
Form D filings for Gladius Therapeutics in 2023 list Michael Seiden as president and director.
Michael Seiden first appears on SEC filings in 2023.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Seiden in the role, so the role may have started earlier or lasted longer.